Lin Chen

20190103176, Apr 4, 2019

Dec 4, 2018

16/209302

- Basel, CH
Jun Chen - Warren NJ, US
Lin Chen - Hopewell Junction NY, US
Qiang Fu - Briarcliff Manor NY, US
Igor Gofman - Croton-on-Hudson NY, US
Steven B. Harris - Briarcliff Manor NY, US
Gary J. Johnson - Lagrangeville NY, US
Paul L. Inman - Nyack NY, US
Qiong Li - Tappan NY, US
Harris Lieber - White Plains NY, US
Derek Lok - Mohegan Lake NY, US
Tony Nguyen - Hopkinton MA, US
Paul M. Ripley - Nanuet NY, US
Gregory Stefkovic - Mahopac NY, US
Hoi-Cheong Steve Sun - Mount Kisco NY, US

G16H 10/60
G06F 16/22
G06F 8/71
G06F 1/16
G06F 13/38
G06F 1/26
G06F 8/65
G16H 40/63
G16H 40/40
A61B 5/145
G06F 13/40
H04L 29/06
G06Q 30/02
G06F 8/61
H04L 29/08

An architecture allows individual system components to be developed and tested individually, i.e., as distinct modules, and to be subsequently combined through standardized electrical and communication interfaces. Any combination of these modules can be implemented to form different products that provide any number of functions, such as an integrated system for monitoring a health condition and/or delivering a medication. The architecture also provides an approach for dynamically updating the product and offering its users the latest generation of technology even after the users have already purchased the product. In particular, the embodiments employ the communication interfaces to also provide connection to a remote network that can update or upgrade the product's software when the product is out in the field.

20180148408, May 31, 2018

Sep 28, 2017

15/718987

- New Brunswick NJ, US
- Cambridge MA, US
Lin Chen - Piscataway NJ, US
Timothy Lewis - Marlborough MA, US
Ben Munoz - Netwonville MA, US
Lili Wang - Chestnut Hill MA, US

C07D 209/48
A61K 31/472
C07D 207/452
C07D 405/12
C07D 401/06
A61K 31/4725
C07D 401/14
G01N 33/50
C07D 217/16
C07D 335/06

A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

20170010882, Jan 12, 2017

Sep 20, 2016

15/270780

- Basel, CH
Jun Chen - Warren NJ, US
Lin Chen - Hopewell Junction NY, US
Qiang Fu - Briarcliff Manor NY, US
Igor Gofman - Croton-on-Hudson NY, US
Steven B. Harris - Briarcliff Manor NY, US
Gary J. Johnson - Lagrangeville NY, US
Paul L. Inman - Nyack NY, US
Qiong Li - Tappan NY, US
Harris Lieber - White Plains NY, US
Derek Lok - Mohegan Lake NY, US
Tony Nguyen - Hopkinton MA, US
Paul M. Ripley - Nanuet NY, US
Gregory Stefkovic - Mahopac NY, US
Hoi-Cheong Steve Sun - Mount Kisco NY, US

G06F 9/445
G06F 19/00
G06F 9/44

An architecture allows individual system components to be developed and tested individually, i.e., as distinct modules, and to be subsequently combined through standardized electrical and communication interfaces. Any combination of these modules can be implemented to form different products that provide any number of functions, such as an integrated system for monitoring a health condition and/or delivering a medication. The architecture also provides an approach for dynamically updating the product and offering its users the latest generation of technology even after the users have already purchased the product. In particular, the embodiments employ the communication interfaces to also provide connection to a remote network that can update or upgrade the product's software when the product is out in the field.

20150143356, May 21, 2015

Jan 28, 2015

14/607631

- Whippany NJ, US
Jun Chen - Warren NJ, US
Lin Chen - Hopewell Junction NY, US
Qiang Fu - Briarcliff Manor NY, US
Igor Gofman - Croton-on-Hudson NY, US
Steven B. Harris - Briarcliff Manor NY, US
Gary J. Johnson - Lagrangeville NY, US
Paul L. Inman - Nyack NY, US
Qiong Li - Tappan NY, US
Harris Lieber - White Plains NY, US
Derek Lok - Mohegan Lake NY, US
Tony Nguyen - Valhalla NY, US
Paul M. Ripley - Nanuet NY, US
Gregory Stefkovic - Mahopac NY, US
Hoi-Cheong Steve Sun - Mount Kisco NY, US

G06F 19/00
G06F 9/445

717170

An architecture allows individual system components to be developed and tested individually, i.e., as distinct modules, and to be subsequently combined through standardized electrical and communication interfaces. Any combination of these modules can be implemented to form different products that provide any number of functions, such as an integrated system for monitoring a health condition and/or delivering a medication. The architecture also provides an approach for dynamically updating the product and offering its users the latest generation of technology even after the users have already purchased the product. In particular, the embodiments employ the communication interfaces to also provide connection to a remote network that can update or upgrade the product's software when the product is out in the field.

20140256767, Sep 11, 2014

Oct 31, 2012

14/355419

- New Brunswick NJ, US
- Cambridge MA, US
Lin Chen - Piscataway NJ, US
Timothy Lewis - Marlborough MA, US
Ben Munoz - Netwonville MA, US
Lili Wang - Chestnut Hill MA, US

THE BROAD INSTITUTE, INC. - Cambridge MA
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY - New Brunswick NJ

C07D 401/14
G01N 33/50
C07D 209/48
C07D 401/06
C07D 217/16

514296, 514307, 546146, 546 99, 514323, 546201, 514417, 548473, 506 10

A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.